Liraglutide for weight management: a critical review of the evidence

To review the efficacy, safety, and clinical applicability of liraglutide for weight management from phase III clinical trials.

[1]  M. Camilleri,et al.  Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis. , 2016, JAMA.

[2]  J. Buse,et al.  Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. , 2016, The New England journal of medicine.

[3]  A. Astrup,et al.  Reduction in the risk of developing type 2 diabetes (T2D) with liraglutide 3.0 mg in people with prediabetes from the SCALE Obesity and Prediabetes randomized, double-blind, placebo-controlled trial , 2016 .

[4]  L. Aronne,et al.  Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial , 2016, International Journal of Obesity.

[5]  G. Umpierrez,et al.  Efficacy and Safety of Liraglutide Versus Placebo as Add-on to Glucose-Lowering Therapy in Patients With Type 2 Diabetes and Moderate Renal Impairment (LIRA-RENAL): A Randomized Clinical Trial , 2015, Diabetes Care.

[6]  R. DeFronzo,et al.  Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial. , 2015, JAMA.

[7]  A. Astrup,et al.  A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. , 2015, The New England journal of medicine.

[8]  C. Apovian,et al.  Pharmacological management of obesity: an endocrine Society clinical practice guideline. , 2015, The Journal of clinical endocrinology and metabolism.

[9]  L. Aronne,et al.  Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study , 2014, International Journal of Obesity.

[10]  Janusz Wnek,et al.  2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults , 2013, Circulation.

[11]  H. Randeva,et al.  Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis , 2013, BMJ Open.

[12]  B. Bode.  An overview of the pharmacokinetics, efficacy and safety of liraglutide. , 2012, Diabetes research and clinical practice.

[13]  J. Jelsing,et al.  Liraglutide: short‐lived effect on gastric emptying—long lasting effects on body weight , 2012, Diabetes, obesity & metabolism.

[14]  N. Marchionni,et al.  Effects of Glucagon-Like Peptide-1 Receptor Agonists on Body Weight: A Meta-Analysis , 2012, Experimental diabetes research.

[15]  A. Astrup,et al.  Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide , 2011, International Journal of Obesity.

[16]  P. O S I T I O N S T A T E M E N T,et al.  Diagnosis and Classification of Diabetes Mellitus , 2011, Diabetes Care.

[17]  A. Astrup,et al.  Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study , 2009, The Lancet.

[18]  G. Sesti,et al.  A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus. , 2009, Clinical therapeutics.

[19]  J. Holst,et al.  Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors , 2005, Diabetologia.

[20]  S. Rössner,et al.  Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men. , 1999, International Journal of Obesity.

[21]  S. Rössner,et al.  Glucagon-like peptide 1 increases the period of postprandial satiety and slows gastric emptying in obese men. , 1998, The American journal of clinical nutrition.

[22]  R. Pederson,et al.  Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. , 1995, Endocrinology.

[23]  J. Holst,et al.  Truncated GLP-1 (proglucagon 78–107-amide) inhibits gastric and pancreatic functions in man , 1993, Digestive Diseases and Sciences.

[24]  S. Bloom,et al.  GLUCAGON-LIKE PEPTIDE-1 7-36: A PHYSIOLOGICAL INCRETIN IN MAN , 1987, The Lancet.

[25]  J. Holst,et al.  Truncated glucagon‐like peptide I, an insulin‐releasing hormone from the distal gut , 1987, FEBS letters.

[26]  M. Mattson,et al.  GLP-1 receptor stimulation depresses heart rate variability and inhibits neurotransmission to cardiac vagal neurons. , 2011, Cardiovascular research.

[27]  P. Zimmet,et al.  Diagnosis and classification of diabetes mellitus , 2002 .